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Abstract Thematrixmetalloproteinase (MMP) enzymesMMP-9, haverelevance to chronic structural airwaychanges
in asthma, which can be generated by structural and in£ammatory cells, and have the ability to degrade proteoglycans
and thuspotentiallyenhance airway ¢brosis and smoothmuscle proliferationthroughtheir ability to release and activate
latent, matrix-boundgrowth factors.Immunostaining for MMP-9 wasundertaken in acetone-¢xed andglycolmethacry-
late-embeddedendobronchialbiopsyspecimensobtainedby ¢breopticbronchoscopyunderlocalanaesthesia.The ¢nd-
ings from 30 asthmatic subjects were compared with those from 18 chronic obstructive pulmonary disease (COPD)
subjects and10 healthy controls.Meanwhile, pulmonary function test and airway responsiveness were performed. Im-
munoreactivity forMMP-9was assessedbyanimage analysis system.Thebiopsy specimens fromasthmatic subjects con-
tained signi¢cantly more eosinophils (P50?001) than those from COPD subjects, and healthy control did not contain
eosinophils.MMP-9 immunoreactivitycould be identi¢ed in endobronchial biopsy specimens from all the asthmatic sub-
jects and 40% of the COPD subjects, butcould not be identi¢ed inhealthycontrols.Gelatinase B (MMP-9) immunoreac-
tivity was located in bronchial epithelium and extracellularmatrix in submucosa, prominent in denuded epithelium.The
immunohistochemical score forMMP-9 was signi¢cantlycorrelatedwith eosinophilic numberinbronchialmucosa.FEV1%
predicted FEV1/FVC (%) (r= 0?52, 0?41, 0?37, respectively P50?01), did not correlate with PD20 FEV1 from asthmatic
subjects.MMP-9 is expressedbybronchial epitheliumandmaybe a important factor foreosinophil in¢ltraed into airway
fromasthma subjects.c 2003 Publishedby Elsevier Science Ltd.
doi:10.1053/rmed.2001.1162, available online at http://www.sciencedirect.com
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Thematrixmetalloproteinases (MMPs) are a large family
of zinc-containing enzymes with well conserved com-
mon structural domains that exhibit degradative activity
against a range of extracellular matrix proteins. There
are four main subclasses: (1) the gelatinases, formerly
known as type IV collagenases, which have activity
against basement membrane collagens and matrix pro-
teoglycans as well as having gelatinolytic activity; (2) the
collagenases which degrade connective tissue collagens;
(3) the stromelysins which have broad substrate speci¢-
city in degrading extracellular matrix proteoglycans, la-
minin, ¢bronectin, elastin and the globular portion of
basement membrane collagens; and (4) a membrane-
bound MMP involved in the activation of gelatinase A.
As a result of their range of activities, MMPs have been
implicated in both normal and pathological structural
remodelling processes such as embryogenesis, cell
migration, tissue repair and tumour necrosis.Their geneCorrespondence should be addressed to:Dr. Zhaosheng Han,
Guangzhou Institute of Respiratory Diseases, ISI Yanjiang Road,
Guangzhou 510120, People’s Republic of China.expression is tightly regulated by cytokines and growth
factors that either enhance (IL-1, TNF,TGF, EGF, FGF or
PDGF) or inhibit (TGF, IL-4) transcription.Furthermore,
MMPs are secreted in a latent form and require cleavage
to a truncated form to exert their proteolytic activity.
ActivatedMMP-9, in cleaving glycosaminoglycans side-
chains from proteoglycans, release stored growth fac-
tors such as basic ¢broblast growth factor 2 (FGF-2)
and transforming growth factor (TGF), both of which
havebeenco-localizedwithin the airways toheparan sul-
phate-containing proteoglycans and decorin. Other
growth factors such as platelet-derived growth factor
(PDGF) and insulin-like growth factor (IGF), which have
relevance to airway ¢brosis, are also known to bind and
be inactivated by proteoglycans. An understanding of
thepresence and localization ofMMPswithin the airways
is thus of pertinence to the understanding of airway ¢-
brosis, one of the structural contributors to airway wall
thickening. Airway wall thickening has been mathemati-
cally linked to increased bronchial hyper-responsiveness
(BHR), a physiological hallmark of the asthmatic process,
and recent studies have speci¢cally related the thickness
of the sub-basement membrane collagen to the level
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cated in the exaggerated progressive decline in lung
function in asthma, a feature underlying the chronicity
of disease.
In view of the potential importance of the MMPs to
the development of structural changes in the airways in
asthma and the identi¢cation of bronchial epithelial as a
potential source of MMP-9, we have used immunohisto-
chemical staining in resin-embedded tissue to explore
the cellular localization and distribution of MMP-9 in pa-
tients with asthma of di¡ering severity, COPD and in
healthy controls.
METHODS
Ten healthy non-atopic volunteers (three men) of mean
(SD) age 28?1 (3?6) years, 18 COPD subjects (10 men) of
mean (SD) 56?2 (8?6) and 30 asthmatic subjects (17 men)
of mean (SD) age 31?0 (8?7) years receiving salbutamol as
their sole medication participated in the study. All of
asthmatics were not receiving inhaled steroids in the
previous 3 months.
All patients and volunteers underwent skin prick test-
ing to common aeroallergens including Dermatopha-
goides pteronyssinus, Aspergillus fumigatus, grass pollen,
cat fur and dog hair (ALK,Denmark) as well as a positive
(histamine) and negative (normal saline) control. A posi-
tive response was taken as a weal of 3mm diameter or
more than thenegative control.Bronchial reactivity test-
ing to histamine to determine the PD20FEV1 value was
undertaken as previously described using a modi¢cation
of themethods of Chaiet al.
Bronchoscopy and tissue processing
Bronchoscopy was performed under local anaesthesia
using an Olympus BFT20 ¢breoptic bronchoscope
(Olympus Co., Tokyo, Japan) as previously described (1)
and in accordance with current NHLBI guidelines (2).
Thus, all subjects received nebulised salbutamol 5mg
and ipratropium bromide 0?5mg prior to bronchoscopy,
and intravenous atropine 0?6mg was administered to
decrease secretions. Topically applied lignocaine (4%)
was used to achieve local anaesthesia and 28% oxygen
was administered via nasal cannulae during the proce-
dure to maintain the PaO2. Bronchial biopsy specimens
were obtained from the right middle lobe or apical
segment of the lower lobe carinae using FB 15C biopsy
forceps (Olympus Co.).The biopsy specimen was imme-
diately placed in ice-cooled acetone containing the
protease inhibitors iodoacetamide (20mM), left for
¢xation at 7208C for 16^20h and then processed into
glycolmethacrylate (GMA) resin for embedding (3) prior
to subsequent immunohistochemical assessment.Immunohistochemical analysis
Immunostaining of GMA-embedded tissue was per-
formed using a technique described previously (3). Thin
(2mm) sectionswere cut in duplicate. Sectionswere ¢rst
treated with a solution of 0?1% sodium azide and 0?3%
hydrogen peroxide to inhibit endogenous peroxidase.
After three washes each of 5min inTris bu¡ered saline
(TBS), pH 7?6, blocking medium (rabbit serum) was ap-
plied for 20min. Sections were then incubated with the
primary antibody (goat anti-human monoclonal antibo-
dies; Dako Ltd, HighWycombe,U.K.) overnight at room
temperature. After threewashes each of 5min, the sec-
ondary antibody (rabbit anti-goat monoclonal antibody)
was added and incubated at room temperature for
20min, then streptavidin^HRP detection system (Dako
Ltd) was added and incubated at room temperature.
After three washes each of 5min, 50ml chromogen was
added and the reaction was terminated after 1min in
water. Subsequently, the sections were counterstained
withhaematoxylin.Control sectionswere always stained
in parallelwith theprimary antibodyomitted. According
to the suppliers, the MMP-9 antibodies do not cross-re-
act with other MMPs in immunohistochemical analysis.
Assessment andquantitation of
immunohistochemical staining
The total number of eosinophil within the submucosa
were counted using light microscopy at 6400 using a
computer-assisted image analysis system (Apple Macin-
tosh Quadra 700 computer; colour Vision 1?6 software,
Improvision, Coventry, U.K.), and the results presented
as cellsmm72.
Immunoreactivity forMMP-9 in the submucosal extra-
cellularmatrix was assessed by twomethods. A compu-
ter-assisted image analysis system was used in, which
two areas of each section (at6400magni¢cation) show-
ing immunoreactivity were selected for measurements
in each biopsy specimen. Muscles and glands were ex-
cluded. The evaluation of immunoreactivity was ex-
pressed as the area immunostained as a percentage of
the total area and always included the subtraction of
background stainingmeasurements in the same areas of
the corresponding control section.The extracellular im-
munostainingwas further evaluatedbyrankingofphoto-
micrographs (6100magni¢cation) and the twomethods
of assessments was compared. The ranking procedure
was undertaken in a blinded approach by two observers
whowere unaware of the coding.
Statistical analysis
Tissue quantities, cell counts andmeasurement of extra-
cellular matrix immunostaining were expressed as med-
ians and ranges.Comparison between groups was made
FIG. 1. MMP-9 immunoreactivityinthebronchialmucosa. (a) A
healthy subject (original magni¢cation 6200), (b) COPD sub-
jects (original magni¢cation 6200) and (c) asthmatic subjects
(originalmagni¢cation6200).
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ranks. A P-value of50?05 was regarded as statistically
signi¢cant. The two methods of assessing extracellular
matrix immunostaining were compared using the
Bland^Altman method after converting the data de-
rived from the image analysis into rank numbers.
RESULTS
Results showed that immunostaining forMMP-9 was po-
sitive in all the asthmatic subjects and 40% COPD sub-
jects, and negative in all the healthy controls (Fig.1). It is
interesting that the immunostaining for MMP-9 was lo-
cated in bronchial epithelium (prominent in denuded
epithelium) andextracellularmatrix, butwas not evident
in eosinophils and neutrophils.The immunohistochemis-
try scoring for MMP-9 was signi¢cantly correlated with
the number of eosinophils, FEV1 % predicted, and FEV1/
FVC% (r=0?52, 0?41, 0?37, respectively P50?01) and
was not correlatedwith PD20FEV1.
Histopathological appearance in bronchial mucosa is
seen in Fig. 2.
DISCUSSION
Using an immunohistochemical approach this study has
investigated the expression of MMP-9. It shows that
MMP-9 is expressed by bronchialmucosa in all asthmatic
subjects and 40% COPD subjects.This indicates that the
speci¢city forMMP-9 immunostaining is low.Because the
immunostaining for MMP-9 is present, even inmild asth-
maticus, this indicates that the sensitivity for MMP-9 is
high.
The abundance and distribution in bronchial tissue of
MMP-9 is explored. Distinct cellular localization could
be identi¢ed which provided evidence for MMP-9 immu-
noreactivity in epithelium, with no apparent localization
to either eosinophils or neutrophils. In addition, there
was distinct evidence of extracellular matrix immunor-
eactivity. The extent of MMP-9 immunoreactivity was
quanti¢ed by two separate methods which gave good
concordance.
MMP-9 activity have been previously detected in per-
ipheral blood eosinophils (5). Eosinophils have been re-
ported to be a source of MMP-9 in airway in£ammation
in asthma, with a greater number expressing MMP-9
mRNA in biopsy specimens from asthmatic subjects
than from normal subjects (21). There have, however,
been no detailed immunohistochemical assessments of
tissue MMP expression in asthma.Our failure to demon-
strate immunolocalization of MMP-9 to eosinophils is,
however, consistent with the discrepancy identi¢ed by
Ohno et al. (6) of mRNA and protein expression for
MMP-9 in eosinophils in thebronchial submucosa of asth-
matic subjects. It is conceivable that the absence ofMMP-9 protein in eosinophils is a re£ection of its complete re-
lease from these cells during extravasation, despite their
continuingmRNA expression. In support of this concept
is the suggestion that MMP-9 plays a central role in eosi-
nophilmigration across basementmembranes (7). A role
for this enzyme in the e¡ective transmigration of T cells
(8) and neutrophils (9) has also been proposed, although
FIG. 2. Histopathological appearance in bronchialmucosa. (a)
Ahealthy subject (originalmagni¢cation6200), (b) COPD sub-
jects (original magni¢cation 6200) and (c) asthmatic subjects
(originalmagni¢cation6200).
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that gelatinase B de¢ciency does not impair neutrophil
migration in vivo (10).While the roles of MMP-9 in vivo re-
main largely undetermined, its deposition in the extra-
cellular matrix characterizes a number of in£ammatory
diseases including bullous pemphigoid inwhich the punc-
tate staining of the extracellular space around weaklystaining cells has been taken as indicative of eosinophil
activation and enzyme secretion (11).
MMP-9 is also known to bind to a number of matrix
components.MMP-9 binds to type I and IV collagens, ge-
latin and laminin 29 while substrates for MMP-9 include
type IV collagen, elastin, and proteoglycan but not type
1 collagen. The staining pattern for MMP-9 in the bron-
chial mucosa [Fig. 1(a)] suggests that this enzyme is
bound by bundles of type I collagen, ¢brils which are
abundant in thematrix butrelatively less so in the lamina
reticularis which is enrichedby types III and V collagen in
asthma (12). Binding of MMP-9 to the collagenous matrix
is proposed to confer retention, stability and bioactivity
for prolonged periods, facilitating its role in pericellular
proteolysis (4).
The extent of matrix immunoreactivity was assessed
by two separate methods: computerized image analysis
and comparative ranking of photomicrographs.Our ana-
lyses indicate that scoring and ranking by eye the degree
of matrix immunoreactivity in tissues through assess-
ment of photomicrographs is as valid as using the more
sophisticatedmethod of computer assisted image analy-
sis of stained tissue sections.Therewas good agreement
between the twomethods of assessment.
This study therefore identi¢es the presence of MMP-9
in the airways of subjects with asthma. It may be an im-
portant factor for eosinophil in¢ltration and declining
lung function.
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